Compare AIHS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIHS | SBFM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.0M |
| IPO Year | 2017 | N/A |
| Metric | AIHS | SBFM |
|---|---|---|
| Price | $1.75 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 23.0K | ★ 31.1K |
| Earning Date | 02-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,389,072.00 | N/A |
| Revenue This Year | N/A | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $1.00 |
| 52 Week High | $8.26 | $3.90 |
| Indicator | AIHS | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 72.72 | 32.97 |
| Support Level | $1.84 | N/A |
| Resistance Level | $3.07 | $1.52 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 67.55 | 9.60 |
Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.